RT @DocOnco: Diese Medikamente werden individuell für jeden Patienten hergestellt. Logistisch und mit großem Zeitaufwand. Der Preis (ca. 32…
Diese Medikamente werden individuell für jeden Patienten hergestellt. Logistisch und mit großem Zeitaufwand. Der Preis (ca. 320.000 Euro) ist sehr hoch. Trotzdem gibt es überzeugende Daten zur Wirksamkeit: https://t.co/awxbV8z2V3
RT @drjgauthier: Does anyone know why the reported rates of ICANS after Kymriah treatment for LBCL are so different between the NEJM public…
Does anyone know why the reported rates of ICANS after Kymriah treatment for LBCL are so different between the NEJM publication (21%) and the FDA package insert? (58%!) 🤔 https://t.co/sdiBTGjONM https://t.co/dNZwfJ6OTj https://t.co/9CpwMSwZgN
Juliet, one of the major CART trials did not even include race/ethnicity in their demographic table. [This happens a lot and it’s not usually because the race/ethnicity perfectly reflects the population] https://t.co/ri9mklkmdL 12/n
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
More #immunotherapy hot takes:
Worth a reboot👇 @MetteMarieHC @n05trum @kim_brixen @SSTbrostrom @kirstinemoll @LMSTdk @EMA_News #cancer
RT @ASTCT: Just over two weeks remain until Dr. Mollie Beck presents an in-depth review of this article: https://t.co/B7CSKuYaKS Register…
Just over two weeks remain until Dr. Mollie Beck presents an in-depth review of this article: https://t.co/B7CSKuYaKS Register for the Online Journal Club, taking place April 17 from 2-3 p.m. CT, here: https://t.co/NAFb9oKsLi https://t.co/Yc3XPCVd8q
RT @i_yakoub_agha: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/S7xpmZkmy2
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/S7xpmZkmy2
#ICYMI this week's #trending article from our #CART feed is 'Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma' from @NEJM https://t.co/HM3D6TSMET See more of the latest in #CARTcell at https://t.co/sEPkK74CaV
RT @ILROGTeam: CAR-T for relapsed/refractory DLBCL demonstrated 52% ORR and impressive 40% CR rate. https://t.co/G0cCfclrdK Short follow-u…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @Olguitxi: Muy pendientes de la organización nacional del tratamiento con medicamentos CAR T https://t.co/SDGXDD7NLV
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
CAR-T cells for R/R Diffuse Large B Cell Lymphomas. Nice results from the Juliet study. https://t.co/jvKoSdAcWp https://t.co/NZvgn1xAmZ
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
Classic example of immortal time bias https://t.co/He3utPs4f5
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @gonen_mithat: Another example of immortal time bias ignored by @NEJM? https://t.co/iDP4CtYqWY
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @gonen_mithat: Another example of immortal time bias ignored by @NEJM? https://t.co/iDP4CtYqWY
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @gonen_mithat: Another example of immortal time bias ignored by @NEJM? https://t.co/iDP4CtYqWY
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @oncology_bg: I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compar…
I have a mind boggling idea. I can prove that any drug is efficacious in cancer without using a control arm. I will compare the K-M graphs of patients who lived for 1 year (arm A) versus those who didn’t (arm B) and show that arm A has a significantly long
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NEJM https://t.co/evO4qi3m88
RT @ILROGTeam: CAR-T for relapsed/refractory DLBCL demonstrated 52% ORR and impressive 40% CR rate. https://t.co/G0cCfclrdK Short follow-u…
RT @Olguitxi: Muy pendientes de la organización nacional del tratamiento con medicamentos CAR T https://t.co/SDGXDD7NLV
RT @gonen_mithat: Another example of immortal time bias ignored by @NEJM? https://t.co/iDP4CtYqWY
RT @gonen_mithat: Another example of immortal time bias ignored by @NEJM? https://t.co/iDP4CtYqWY
RT @ILROGTeam: CAR-T for relapsed/refractory DLBCL demonstrated 52% ORR and impressive 40% CR rate. https://t.co/G0cCfclrdK Short follow-u…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @danleisman: Putting aside the statistical problems with this one, can someone on #medtwitter #EpiTwitter explain to me why a trial mean…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
Putting aside the statistical problems with this one, can someone on #medtwitter #EpiTwitter explain to me why a trial meant to show efficacy would ever be conducted without a control group?
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @gonen_mithat: Another example of immortal time bias ignored by @NEJM? https://t.co/iDP4CtYqWY
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
Another example of immortal time bias ignored by @NEJM?
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @ILROGTeam: CAR-T for relapsed/refractory DLBCL demonstrated 52% ORR and impressive 40% CR rate. https://t.co/G0cCfclrdK Short follow-u…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @Olguitxi: Muy pendientes de la organización nacional del tratamiento con medicamentos CAR T https://t.co/SDGXDD7NLV
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @nunottav: ⚠️ ALERTA ⚠️ ⚠️ Tisagenlecleucel ⚠️ Temos um novo nome de fármaco mais impronunciável de sempre. https://t.co/t7aoZvanKt
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
Muy pendientes de la organización nacional del tratamiento con medicamentos CAR T
⚠️ ALERTA ⚠️ ⚠️ Tisagenlecleucel ⚠️ Temos um novo nome de fármaco mais impronunciável de sempre.
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
RT @NEJM: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates o…
In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. Full study: https://t.co/4uzijXWskv
RT @Zihai: Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma - clinical response seen across the board. https:…
RT @NEJM: JULIET trial results: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma i…
RT @ILROGTeam: CAR-T for relapsed/refractory DLBCL demonstrated 52% ORR and impressive 40% CR rate. https://t.co/G0cCfclrdK Short follow-u…
RT @ILROGTeam: CAR-T for relapsed/refractory DLBCL demonstrated 52% ORR and impressive 40% CR rate. https://t.co/G0cCfclrdK Short follow-u…